Evidence map›Paper›PMID 39711963›Full record

ArticleFrontiers in oncology2024

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of

Stavroula Smilkou, Loukas Kaklamanis, Ioanna Balgouranidou, Helena Linardou, Alkistis Maria Papatheodoridi, Flora Zagouri, Evangelia Razis, Stylianos Kakolyris, Amanda Psyrri, Christos Papadimitriou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stavroula SmilkouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Loukas KaklamanisDepartment of Pathology, Onassis Cardiac Surgery Center, Athens, Greece.
Ioanna BalgouranidouDepartment of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece.
Helena LinardouOncology Unit, Metropolitan Hospital, Athens, Greece.
Alkistis Maria PapatheodoridiDepartment of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Flora ZagouriDepartment of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Evangelia RazisThird Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
Stylianos KakolyrisDepartment of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece.
Amanda PsyrriSection of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Attikon University Hospital, Athens, Greece.
Christos PapadimitriouOncology Unit, 2nd Department of Surgery, School of Medicine, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Athina MarkouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Evi LianidouAnalysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Detection of Patients and methods: We analyzed 42 gDNAs from primary tumors (FFPEs), 29 plasma-cfDNA samples, and 29 paired CTC-derived gDNAs, all from patients with ER+ metastatic breast cancer, and plasma from 10 healthy donors. The same blood draws were used for CTC isolation using EpCAM beads for positive immunomagnetic enrichment. All FFPEs and plasma-cfDNA samples were analyzed in parallel for Results: In gDNAs from FFPEs, using ultrasensitive real-time PCR, the p.E545K mutation was detected in 22/42(52.4%), and the p.E542K and p.H1047R mutations were detected in 14/42(33.3%) and 16/42(38.1%), respectively. Using ddPCR, the p.E545K mutation was detected in 22/42(52.4%), p.E542K in 17/42(40.5%), and p.H1047R in 19/42(45.2%) samples, revealing a concordance between the two methodologies of 81%, 78.6% and 78.6% for each mutation respectively. In plasma-cfDNA, using ultrasensitive real-time PCR, the p.E545K mutation was detected in 11/29(38%) and both p.E542K and p.H1047R mutations in 2/29(6.9%).In the same plasma-cfDNA samples using ddPCR, p.E545K was detected in 1/29(3.5%), p.E542K in 2/29(6.9%), and p.H1047R in 3/29(10.5%) samples, revealing a concordance of 65.5%,100% and 93.1% for each mutation respectively. In paired CTC-derived gDNAs p.E545K was detected in 11/29(38%), p.E542K in 3/29(10.3%), and p.H1047R in 7/29(24.1%) samples. Conclusions: This low-cost, high-throughput and ultrasensitive real-time PCR assay provides accurate and specific detection of

Indexed as

breast cancercirculating tumor cellsDNA melting curve analysisdroplet digital PCRliquid biopsyPIK3CA mutationsplasma cell-free DNAultrasensitive molecular assay

Identifiers

PMID39711963
PMCPMC11659196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.